Shile Zhang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12069525/publications.pdf

Version: 2024-02-01

623188 996533 6,489 16 14 15 citations h-index g-index papers 16 16 16 11890 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	The MicroRNA Spectrum in 12 Body Fluids. Clinical Chemistry, 2010, 56, 1733-1741.	1.5	2,332
2	Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 4402-4407.	3.3	1,089
3	Export of microRNAs and microRNA-protective protein by mammalian cells. Nucleic Acids Research, 2010, 38, 7248-7259.	6.5	907
4	Comprehensive Genomic Analysis of Rhabdomyosarcoma Reveals a Landscape of Alterations Affecting a Common Genetic Axis in Fusion-Positive and Fusion-Negative Tumors. Cancer Discovery, 2014, 4, 216-231.	7.7	596
5	Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nature Genetics, 2015, 47, 864-871.	9.4	451
6	Genetic predisposition to neuroblastoma mediated by a LMO1 super-enhancer polymorphism. Nature, 2015, 528, 418-421.	13.7	263
7	Complexity of the microRNA repertoire revealed by next-generation sequencing. Rna, 2010, 16, 2170-2180.	1.6	246
8	Surface Plasmon Resonance Biosensor for Rapid Label-Free Detection of Microribonucleic Acid at Subfemtomole Level. Analytical Chemistry, 2010, 82, 10110-10115.	3.2	188
9	Systems biology of interstitial lung diseases: integration of mRNA and microRNA expression changes. BMC Medical Genomics, 2011, 4, 8.	0.7	105
10	MultiDimensional ClinOmics for Precision Therapy of Children and Adolescent Young Adults with Relapsed and Refractory Cancer: A Report from the Center for Cancer Research. Clinical Cancer Research, 2016, 22, 3810-3820.	3.2	99
11	Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T-Cell Receptors in High-Risk <i>MYCN</i> -Not-Amplified Human Neuroblastoma. Clinical Cancer Research, 2018, 24, 5673-5684.	3.2	92
12	Aurora B kinase is a potent and selective target in MYCN-driven neuroblastoma. Oncotarget, 2015, 6, 35247-35262.	0.8	52
13	MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma. Cancer Letters, 2016, 371, 214-224.	3.2	46
14	The Genetics of Splicing in Neuroblastoma. Cancer Discovery, 2015, 5, 380-395.	7.7	20
15	The Significance of Transcriptome Sequencing in Personalized Cancer Medicine., 2014,, 49-64.		2
16	Mammalian cells in culture actively export specific microRNAs. Nature Precedings, 2009, , .	0.1	1